SECsense Logo

MEI Pharma, Inc. 8-K Filing Insights: Key Updates for Investors

$MEIP
Form 8-K
Filed on: 2025-02-12
Source
MEI Pharma, Inc. 8-K Filing Insights: Key Updates for Investors

Here are the key insights extracted from the provided section of the financial report:

  1. Entity Information:
  • Company Name: MEI Pharma, Inc.
  • CIK: 0001262104
  • SEC File Number: 001-41827
  • EIN: 51-0407811
  • Address: 9920 Pacific Heights Blvd., Suite 150, San Diego, CA 92121
  • Phone Number: 858-369-7100
  1. Filing Type:
  • Form Type: 8-K (a current report used to disclose any material events)
  1. Reporting Period:
  • Filing Date: February 12, 2025
  • Period Start Date: February 12, 2025
  • Period End Date: February 12, 2025
  1. Securities Information:
  • Type of Security: Common Stock
  • Par Value: $0.00000002
  • Ticker Symbol: MEIP
  • Exchange: NASDAQ
  1. Contextual Elements:
  • The document is formatted in XBRL (eXtensible Business Reporting Language), which indicates that the data can be easily processed and analyzed by software.

Summary:

This report indicates that MEI Pharma, Inc. has filed an 8-K on February 12, 2025, indicating a significant event or change that investors should be aware of. The company is publicly traded on NASDAQ under the ticker MEIP, and the filing includes key corporate information and the specific date of the report, which aligns with a singular reporting instance.

Implications:

Investors should review the details of the 8-K filing to understand the nature of the event being reported, which may affect the company's financial condition or stock performance.